Will These Biotech Stocks Soar Or Slump This Month?

(RTTNews) - Clinical trial data is an important catalyst, and trial results or any update on the clinical studies can send the biotech stocks soaring or stumbling depending upon the news.

Listed below are some of the biotech/pharma companies slated to report clinical trial results this month.

1. Bellerophon Therapeutics Inc. (BLPH)

Bellerophon is a late-stage biotherapeutics company.

The Company is developing INOpulse delivery system for the treatment of patients with pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD).

Near-term Catalyst:

A phase III INOvation-1 study evaluating INOpulse in patients with pulmonary arterial hypertension is underway. Readout of the interim analysis of this trial is expected in mid-2018, with top-line data from the full study anticipated around the end of 2018.

BLPH closed Friday's trading at $2.53, up 4.98%.

2. Pulmatrix Inc. (PULM)

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE technology.

Near-term Catalyst:

A single dose escalation phase 1/1b study of Pulmazole (PUR1900) - an inhaled iSPERSE formulation of the anti-fungal drug Itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma is underway - with top line results expected to be available in mid-2018.

PULM closed Friday's trading at $0.55, up 8.24%.

3. ObsEva SA (OBSV)

ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy.

The Company's lead product candidate is OBE2109 for the treatment of pain associated with endometriosis, and for treating heavy menstrual bleeding associated with uterine fibroids (UF) in pre-menopausal women.

Near-term Catalyst:

A phase IIb clinical trial of OBE2109 for the treatment of pain associated with endometriosis, dubbed EDELWEISS is underway - with 12-week results expected this month.

OBSV closed Friday's trading at $14.49, up 8.30%.

4. Zafgen Inc. (ZFGN)

Zafgen is a clinical-stage biopharmaceutical company developing novel therapies for patients affected by complex metabolic diseases.

The Company's lead product candidate is ZGN-1061, under phase II proof of concept trial for type 2 diabetes.

Near-term Catalyst:

Full topline data from the phase II proof-of-concept trial of ZGN-1061 in type 2 diabetes is expected mid-year 2018.

ZFGN closed Friday's trading at $6.62, down 2.36%.